Accuray, Inc. Hits 52-Week Low at USD 1.10 Amidst Declining Performance

Accuray, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.10 on November 6, 2025. This significant drop highlights the company's ongoing struggles, as it has experienced a 31.46% decline in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 17.53% during the same period.
With a market capitalization of USD 175 million, Accuray's financial metrics reveal a challenging landscape. The company is currently loss-making, reflected in its undefined P/E ratio, and it has a high Debt to EBITDA ratio of 5.74 times, indicating potential difficulties in servicing its debt. Additionally, the average Return on Capital Employed (ROCE) stands at a modest 6.81%, suggesting weak long-term fundamental strength.

Despite a 98.3% increase in profits over the past year, the stock has generated negative returns of 19.44%, underlining its underperformance relative to broader market trends. The stock's previous 52-week high was USD 2.95, further emphasizing the recent downturn in its market position.